← Back to headlines
H.C. Wainwright Adjusts BioXcel Therapeutics Outlook Amid Capital Structure Concerns
H.C. Wainwright has revised its outlook for BioXcel Therapeutics, Inc. (BTAI) following concerns regarding the company's capital structure. The adjustment reflects the analyst firm's updated assessment of the company's financial health.
17 Apr, 13:36 — 17 Apr, 13:36
Sources
Showing 1 of 1 sources
